Latest news and press releases about PTC Therapeutics, Inc. (PTCT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Price
| Price | $67.35 |
| Market Cap | $5.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -33.74 |
| EV / EBITDA | 30.47 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 21.72% |
| Return on Invested Capital | 2.61% |
| Return on Assets | -1.18% |
| Gross Margin | 82.14% |
| Operating Margin | 11.52% |
| Net Margin | -3.80% |
Related companies: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks